|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-6-6
|
|
pubmed:abstractText |
Rebound in psoriasis is, by definition, a rapid worsening of disease following the discontinuation of therapy for psoriasis; it occurs following the abrupt discontinuation of many therapies. To prevent rebound on discontinuation of efalizumab, this study evaluated the effectiveness of transitioning patients to an alternative psoriasis therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0011-9059
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
637-48
|
|
pubmed:meshHeading |
pubmed-meshheading:17550570-Adolescent,
pubmed-meshheading:17550570-Adult,
pubmed-meshheading:17550570-Aged,
pubmed-meshheading:17550570-Antibodies, Monoclonal,
pubmed-meshheading:17550570-Dermatologic Agents,
pubmed-meshheading:17550570-Drug Administration Schedule,
pubmed-meshheading:17550570-Female,
pubmed-meshheading:17550570-Humans,
pubmed-meshheading:17550570-Injections, Subcutaneous,
pubmed-meshheading:17550570-Male,
pubmed-meshheading:17550570-Middle Aged,
pubmed-meshheading:17550570-PUVA Therapy,
pubmed-meshheading:17550570-Psoriasis,
pubmed-meshheading:17550570-Recurrence,
pubmed-meshheading:17550570-Severity of Illness Index,
pubmed-meshheading:17550570-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
|
|
pubmed:affiliation |
Baylor University Medical Center, Dallas, Texas, USA. amresearch@texasderm.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
